ERBB2 and breast carcinoma: EGFR mutations or ALK rearrangements in lung cancer, BRAF V600E mutations in metastatic melanoma and breast cancer patients harbouring HER2 amplifications are examples of therapeutic biomarkers routinely used in the adult population [36–38].